Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $19.2 million.

  • Sangamo Therapeutics' Cash from Financing Activities rose 956009.85% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 19203.82%. This contributed to the annual value of $28.4 million for FY2024, which is 9452.29% up from last year.
  • As of Q3 2025, Sangamo Therapeutics' Cash from Financing Activities stood at $19.2 million, which was up 956009.85% from $28.6 million recorded in Q2 2025.
  • Sangamo Therapeutics' Cash from Financing Activities' 5-year high stood at $43.8 million during Q3 2022, with a 5-year trough of -$1.6 million in Q1 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $8.0 million (2023), whereas its average is $11.4 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Cash from Financing Activities plummeted by 11028.55% in 2022, and later skyrocketed by 956009.85% in 2025.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Cash from Financing Activities stood at $2.1 million in 2021, then skyrocketed by 824.95% to $19.5 million in 2022, then tumbled by 99.15% to $167000.0 in 2023, then soared by 4086.23% to $7.0 million in 2024, then soared by 174.7% to $19.2 million in 2025.
  • Its Cash from Financing Activities was $19.2 million in Q3 2025, compared to $28.6 million in Q2 2025 and $8.1 million in Q1 2025.